Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PRKCG | P05129 | 1/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | FES | P07332 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | ROS1 | P08922 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.36 |
| ▸ | FER | P16591 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MARK3 | P27448 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30731275 | 0.87 | AXL (0.41) | AXLDYRK1APLK4AURKAJAK2 | |
| SCHEMBL22554210 | 0.87 | AXL (0.41) | AXLDYRK1APLK4AURKAJAK2 | |
| SCHEMBL13976070 | 0.81 | PRMT5 (0.43) | AXLDYRK1APLK4AURKAJAK2 | |
| SCHEMBL84584 | 0.81 | MET (0.42) | AXLITKPRMT5WDR77 | |
| SCHEMBL19105605 | 0.79 | MAP3K12 (0.41) | AXLDYRK1AJAK2ROCK2PRKD3 | |
| SCHEMBL84420 | 0.79 | MAP3K12 (0.41) | JAK2ITKPRMT5WDR77 | |
| SCHEMBL18352451 | 0.77 | MAP3K12 (0.35) | AXLDYRK1ACLK1SGK1CDK8 | |
| SCHEMBL91446 | 0.77 | AXL (0.47) | AXLDYRK1APLK4AURKAJAK2 | |
| SCHEMBL24012829 | 0.76 | PRMT5 (0.41) | DYRK1ACLK1SGK1CAMKK2HASPIN | |
| SCHEMBL13523638 | 0.76 | MAP3K12 (0.47) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021223736-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-11-11 | — | — | WO | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | AXL 135/4885DYRK1A 776/4885PLK4 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.